Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
34.62
+1.63 (4.94%)
Apr 30, 2026, 4:00 PM EDT - Market closed
Nanobiotix Revenue
In the year 2025, Nanobiotix had annual revenue of 32.59M EUR. Nanobiotix had revenue of 5.96M in the half year ending December 31, 2025, a decrease of -81.91%.
Revenue (ttm)
32.59M EUR
Revenue Growth
n/a
P/S Ratio
42.70
Revenue / Employee
316,437 EUR
Employees
103
Market Cap
1.63B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.59M | 39.78M | - |
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -242.53K | -6.52% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.36% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 2.59M | 1,398.23% |
| Dec 31, 2013 | 184.94K | -785.67K | -80.95% |
| Dec 31, 2012 | 970.61K | -389.70K | -28.65% |
| Dec 31, 2011 | 1.36M | 225.46K | 19.87% |
| Dec 31, 2010 | 1.13M | -1.63M | -59.00% |
| Dec 31, 2009 | 2.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Innoviva | 411.33M |
| Nurix Therapeutics | 71.78M |
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Agios Pharmaceuticals | 66.05M |
| Nuvation Bio | 62.90M |
| Generate Biomedicines | 31.89M |
NBTX News
- 11 days ago - Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery - Nasdaq
- 11 days ago - Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - GlobeNewsWire
- 23 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 4 weeks ago - Nanobiotix Earnings Call Transcript: H2 2025 - Transcripts
- 4 weeks ago - Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down - Nasdaq
- 4 weeks ago - NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 - GlobeNewsWire
- 5 weeks ago - Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process - Benzinga